Guinea-Bissau
Tuberculosis profile
| High HIV burden |
Population  2013 1.7 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.2 (0.57–1.8) 71 (34–107)
Mortality (HIV+TB only) 1.4 (0.89–1.9) 80 (52–114)
Prevalence  (includes HIV+TB) 8.8 (4.3–15) 515 (251–872)
Incidence  (includes HIV+TB) 6.6 (4.6–8.8) 387 (273–514)
Incidence (HIV+TB only) 2.7 (1.9–3.6) 158 (111–214)
Case detection, all forms (%) 32 (24–45)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 1.9 (0.1–5.3) 20 (0.1–40)
MDR-TB cases among notified pulmonary
TB cases
37 (2–100) 10 (0–20)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 1 485   41
Pulmonary, clinically diagnosed 474   0
Extrapulmonary 87   0
       
Total new and relapse 2 087    
Previously treated, excluding relapses 8    
Total cases notified 2 095    
Among 2 046 new cases:
96 (5%) cases aged under 15 years; male:female ratio: 1.6
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 94 (6%) 33 (67%) 150
Laboratory-confirmed RR-/MDR-TB cases     15
Patients started on MDR-TB treatment     15
TB/HIV 2013 Number (%)
TB patients with known HIV status 1 278 (61)
HIV-positive TB patients 524 (41)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 226 (43)
HIV-positive TB patients on antiretroviral therapy (ART) 104 (20)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 71
Previously treated cases, excluding relapse, registered in 2012 60
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 0
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 1.2
Culture (per 5 million population) 2.9
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) 3.6
% Funded domestically  
% Funded internationally 100%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-04-21 Data: www.who.int/tb/data